ClinicalTrials.govpublic full text
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
multiple myeloma, etentamig, daratumumab, lenalidomide, dexamethasone, interventional, phase2, phase3
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗Related documents
Record · ID 847346
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.